Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

On this week's Business of Biotech episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's ...

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

The global vaccine clinical trials landscape has transformed profoundly since the COVID-19 pandemic, shifting from a traditionally conservative field to an innovation-driven sector marked by rapid ...

Clinical trial participation is fundamental to medical progress, yet improving enrolment across diverse populations remains a persistent challenge. Early phase clinical trials — particularly Phase 1 ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

This whitepaper provides a comprehensive overview of how sponsors can accelerate clinical trial start-up in Australia, leveraging the nation’s unique strengths as a global hub for clinical research.